PMID- 35707517
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 15
DP  - 2022
TI  - An Effective Hormonal Therapy for a Patient with Estrogen Receptor 1 
      (ESR1)-Amplified Metastatic Ovarian Cancer: A Case Report.
PG  - 643-649
LID - 10.2147/OTT.S363856 [doi]
AB  - Hormonal therapy is an important treatment option for estrogen receptor 
      (ER)-positive patients with advanced ovarian cancer. Although ER overexpression 
      has been previously used as an indicator for hormonal therapy, the clinical 
      outcomes of advanced ovarian cancer patients receiving hormonal therapy remain 
      unsatisfactory. Additional biomarkers for screening patients are needed to 
      improve its efficacy. In this study, we reported a metastatic ovarian cancer case 
      with estrogen receptor 1 (ESR1) gene amplification and protein overexpression, 
      which showed sustained partial response to hormonal therapy, including letrozole 
      and tamoxifen, and displayed an overall survival of 47 months. The response to 
      the therapy was evaluated by imageological examinations, cancer antigen-125 
      (CA-125) tests, and circulating tumor DNA (ctDNA) sequencing using capture-based 
      hybrid next-generation sequencing. Our clinical data suggested that ESR1 
      amplification might be a potential predictor of response to hormonal therapy in 
      ovarian cancer. The combination of tumor detection techniques including imaging, 
      CA-125 and ctDNA would enable confirmation of tumor response with high 
      confidence.
CI  - (c) 2022 Wang et al.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Medical Oncology, the Second Affiliated Hospital of Dalian Medical 
      University, Dalian, Liaoning, People's Republic of China.
FAU - Tan, Shuang
AU  - Tan S
AD  - Department of Gynecology, the Second Affiliated Hospital of Dalian Medical 
      University, Dalian, Liaoning, People's Republic of China.
FAU - Pan, Evenki
AU  - Pan E
AD  - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, Jiangsu, 
      People's Republic of China.
FAU - Ma, Yutong
AU  - Ma Y
AUID- ORCID: 0000-0002-0622-2793
AD  - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, Jiangsu, 
      People's Republic of China.
FAU - Wu, Xue
AU  - Wu X
AD  - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, Jiangsu, 
      People's Republic of China.
FAU - Yu, Zhe
AU  - Yu Z
AD  - Department of Medical Oncology, the Second Affiliated Hospital of Dalian Medical 
      University, Dalian, Liaoning, People's Republic of China.
FAU - Jiang, Kui
AU  - Jiang K
AD  - Department of Medical Oncology, the Second Affiliated Hospital of Dalian Medical 
      University, Dalian, Liaoning, People's Republic of China.
LA  - eng
PT  - Case Reports
DEP - 20220609
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC9191580
OTO - NOTNLM
OT  - ESR1 amplification
OT  - circulating tumor DNA
OT  - hormonal therapy
OT  - letrozole
OT  - ovarian cancer
OT  - tamoxifen
COIS- Evenki Pan, Yutong Ma, and Xue Wu are employees of Nanjing Geneseeq Technology 
      Inc., China. The other authors declare no conflicts of interest related to this 
      case report.
EDAT- 2022/06/17 06:00
MHDA- 2022/06/17 06:01
PMCR- 2022/06/09
CRDT- 2022/06/16 02:40
PHST- 2022/03/15 00:00 [received]
PHST- 2022/05/27 00:00 [accepted]
PHST- 2022/06/16 02:40 [entrez]
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/06/17 06:01 [medline]
PHST- 2022/06/09 00:00 [pmc-release]
AID - 363856 [pii]
AID - 10.2147/OTT.S363856 [doi]
PST - epublish
SO  - Onco Targets Ther. 2022 Jun 9;15:643-649. doi: 10.2147/OTT.S363856. eCollection 
      2022.